Page 10 - Protein Sciences News Today

ImmunityBio (NASDAQ:IBRX – Get Rating) and Bio-Techne (NASDAQ:TECH – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk. Profitability This table compares ImmunityBio and Bio-Techne’s net margins, return on equity […]

Bio-Techne Co. (NASDAQ:TECH – Get Rating) – SVB Leerink cut their Q3 2024 earnings estimates for shares of Bio-Techne in a research report issued on Sunday, May 14th. SVB Leerink analyst P. Souda now expects that the biotechnology company will earn $0.55 per share for the quarter, down from their prior forecast of $0.57. SVB […]

StockNews.com initiated coverage on shares of Bio-Techne (NASDAQ:TECH – Get Rating) in a research note published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Several other research analysts have also weighed in on the stock. Robert W. Baird increased their price objective on shares of Bio-Techne from $99.00 to […]

Jennison Associates LLC lifted its holdings in Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 198.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 160,972 shares of the biotechnology company’s stock after buying an additional 106,962 shares during the quarter. Jennison Associates LLC’s holdings in Bio-Techne were worth $13,341,000 at the end of the most […]

Lwmg LLC purchased a new stake in shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,285 shares of the biotechnology company’s stock, valued at approximately $1,267,000. A number of other hedge funds and other […]

MINNEAPOLIS, May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets... | May 12, 2023

Bio-Techne Co. (NASDAQ:TECH – Get Rating) announced a quarterly dividend on Wednesday, May 3rd, Zacks reports. Investors of record on Monday, May 15th will be given a dividend of 0.08 per share by the biotechnology company on Friday, May 26th. This represents a $0.32 dividend on an annualized basis and a yield of 0.39%. The […]

California Public Employees Retirement System increased its position in shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) by 302.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 348,072 shares of the biotechnology company’s stock after purchasing an additional 261,515 shares during the quarter. California Public Employees […]

Bio-Techne (NASDAQ:TECH – Get Rating) had its price objective increased by Robert W. Baird from $99.00 to $100.00 in a report released on Thursday, The Fly reports. Other equities research analysts have also recently issued research reports about the stock. SVB Leerink cut their price objective on shares of Bio-Techne from $125.00 to $110.00 and […]

Aziyo Biologics (NASDAQ:AZYO – Get Rating) and Bio-Techne (NASDAQ:TECH – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Valuation and Earnings This table compares Aziyo Biologics and Bio-Techne’s revenue, […]